Iovance's Lifileucel-Pembrolizumab Combination Shows 62.5% Response Rate in Phase 2 Melanoma Trial

Bitget2026/10/23 14:15

By:Bitget

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Iovance Biotherapeutics presented final Phase 2 results for lifileucel combined with pembrolizumab in frontline advanced melanoma at ESMO on October 23, 2026.
The combination produced durable tumor responses, with safety consistent with the treatments' known profiles.
Results support the ongoing TILVANCE-301 Phase 3 trial seeking to expand lifileucel's use into frontline advanced melanoma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610231015PRIMZONEFULLFEED9851785) on October 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Iovance's Lifileucel-Pembrolizumab Combination Shows 62.5% Response Rate in Phase 2 Melanoma Trial

You may also like

Crypto prices